DE69723429T3 - Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS - Google Patents

Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS Download PDF

Info

Publication number
DE69723429T3
DE69723429T3 DE69723429T DE69723429T DE69723429T3 DE 69723429 T3 DE69723429 T3 DE 69723429T3 DE 69723429 T DE69723429 T DE 69723429T DE 69723429 T DE69723429 T DE 69723429T DE 69723429 T3 DE69723429 T3 DE 69723429T3
Authority
DE
Germany
Prior art keywords
bmp
res
xaa
morphogen
gdf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69723429T
Other languages
German (de)
English (en)
Other versions
DE69723429T2 (de
DE69723429D1 (de
Inventor
F. Marc CHARETTE
P. Seth FINKLESTEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Stryker Corp
Original Assignee
General Hospital Corp
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24485972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69723429(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Curis Inc filed Critical General Hospital Corp
Publication of DE69723429D1 publication Critical patent/DE69723429D1/de
Publication of DE69723429T2 publication Critical patent/DE69723429T2/de
Application granted granted Critical
Publication of DE69723429T3 publication Critical patent/DE69723429T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of Electric Motors In General (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Protection Of Generators And Motors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69723429T 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS Expired - Lifetime DE69723429T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
US620444 1996-03-22
PCT/US1997/004177 WO1997034626A1 (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Publications (3)

Publication Number Publication Date
DE69723429D1 DE69723429D1 (de) 2003-08-14
DE69723429T2 DE69723429T2 (de) 2004-04-22
DE69723429T3 true DE69723429T3 (de) 2007-09-20

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69723429T Expired - Lifetime DE69723429T3 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
DE69740089T Expired - Lifetime DE69740089D1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen Erholung der motorischen Koordiination, der Sprache oder der Sinneswahrnehmung nach Trauma oder Ischämie des ZNS

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69740089T Expired - Lifetime DE69740089D1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen Erholung der motorischen Koordiination, der Sprache oder der Sinneswahrnehmung nach Trauma oder Ischämie des ZNS

Country Status (11)

Country Link
US (4) US6214796B1 (en:Method)
EP (3) EP1364655B1 (en:Method)
JP (2) JP2000507939A (en:Method)
KR (1) KR20000064752A (en:Method)
CN (1) CN1181885C (en:Method)
AT (2) ATE493141T1 (en:Method)
AU (2) AU734312B2 (en:Method)
CA (2) CA2249596C (en:Method)
DE (2) DE69723429T3 (en:Method)
ES (1) ES2201287T5 (en:Method)
WO (2) WO1997034626A1 (en:Method)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
EP2272959A1 (en) 1993-05-12 2011-01-12 Genetics Institute, LLC BMP-11 compositions
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
ES2255059T3 (es) 1993-12-07 2006-06-16 Genetics Institute, Llc Bmp-12, bmp-13 y composiciones suyas inductoras de tendon.
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
DK0980252T3 (da) 1997-05-05 2005-01-31 Curis Inc Terapier til akut nyresvigt
EP1988395A1 (en) * 1997-05-30 2008-11-05 Curis, Inc. Methods for evaluating tissue morphogenesis and morphogenic activity
CA2314423A1 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
JP2003507349A (ja) * 1999-08-18 2003-02-25 ザ ゼネラル ホスピタル コーポレーション 中枢神経系への損傷からの回復を促進する方法、組成物およびキット
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
JP2003534385A (ja) 2000-06-01 2003-11-18 チルドレンズ メディカル センター コーポレーション 被験者の神経に有益な効果をもたらす方法および組成物
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
ATE393573T1 (de) 2001-06-01 2008-05-15 Wyeth Corp Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
CA2448591A1 (en) * 2001-06-01 2002-12-12 Xcyte Therapies, Inc. T cell induced tissue repair and regeneration
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
EP1569683B1 (en) 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
AU2003300359A1 (en) 2003-05-08 2004-12-13 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
EP1773871B1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
US20080108547A1 (en) * 2004-07-20 2008-05-08 Taylor Ii Larry Edmund Protease Inhibitor
WO2006011600A1 (ja) * 2004-07-29 2006-02-02 Anges Mg, Inc. 脳機能改善のための医薬および方法
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
PT2497780E (pt) 2005-09-20 2015-08-20 Thrasos Innovation Inc Compostos relacionados com tdf e seus análogos
ES2534672T3 (es) 2005-11-12 2015-04-27 The Board Of Trustees Of The Leland Métodos relacionados con FGF2 para diagnosticar y tratar la depresión
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
ES2402672T3 (es) * 2007-01-25 2013-05-07 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Uso del GDF-5 para el mejoramiento o el mantenimiento del aspecto dérmico
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
WO2009129101A1 (en) * 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
US20100204124A1 (en) * 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
US20100204123A1 (en) * 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
WO2010103070A2 (en) 2009-03-12 2010-09-16 Charité - Universitätsmedizin Berlin Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
JP2013518808A (ja) 2009-09-17 2013-05-23 ストライカー コーポレイション 骨形成タンパク質のｐＨを制御するための緩衝液
EP2516456A1 (en) 2009-12-22 2012-10-31 Stryker Corporation Bmp-7 variants with reduced immunogenicity
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
EP3124039B1 (en) 2010-08-20 2018-01-31 Wyeth LLC Designer osteogenic proteins
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
RU2014105513A (ru) * 2011-07-19 2015-08-27 Трасос Инновэйшн, Инк. Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3007719B1 (en) * 2013-06-11 2021-03-17 President and Fellows of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN109803977B (zh) 2016-08-17 2023-03-17 菲克特生物科学股份有限公司 核酸产品及其施用方法
JP2021529835A (ja) * 2018-07-03 2021-11-04 ベンチュリス セラピューティクス， インク．Ｖｅｎｔｕｒｉｓ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 脳卒中を治療するための組成物及び方法
CN115190886A (zh) * 2020-02-20 2022-10-14 马斯特里赫特大学 循环bmp10（骨形态发生蛋白10）的检测方法
CA3179133A1 (en) * 2020-05-19 2021-11-25 Elevian, Inc. Methods and compositions for treating stroke
WO2024259004A1 (en) * 2023-06-13 2024-12-19 Bedford Research Foundation Systems and methods of cell transport at ambient temperature

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
WO1990000619A1 (en) 1988-07-08 1990-01-25 University College London Analysis of cell modifying substances
WO1990000900A1 (en) 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
JP2845346B2 (ja) 1989-10-17 1999-01-13 ストライカー・コーポレーション 骨形成具
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
AU666291B2 (en) 1990-06-15 1996-02-08 Carnegie Institution Of Washington Gdf-1
DE69133338T2 (de) 1990-09-26 2004-04-15 Genetics Institute, LLC, Cambridge Bmp-5-derivate
ES2120964T3 (es) 1990-10-18 1998-11-16 Stryker Corp Peptidos osteogenicos.
WO1992008480A1 (en) 1990-11-16 1992-05-29 Celtrix Pharmaceuticals, Inc. A β-TYPE TRANSFORMING GROWTH FACTOR
DE69132918T2 (de) 1990-11-27 2002-10-31 American National Red Cross, Washington Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
AU651421B2 (en) 1990-11-30 1994-07-21 Celtrix Pharmaceuticals, Inc. Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair
EP0575555B1 (en) * 1991-03-11 2001-07-18 Curis, Inc. Protein-induced morphogenesis
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
WO1992020371A1 (en) 1991-05-10 1992-11-26 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
JPH06500574A (ja) 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
EP0591392B1 (en) 1991-06-21 1996-09-11 Genetics Institute, Inc. Pharmaceutical formulations of osteogenic proteins
ES2127757T3 (es) 1991-06-25 1999-05-01 Genetics Inst Composiciones bmp-9.
DE69231062T3 (de) * 1991-08-30 2004-07-29 Creative Biomolecules, Inc., Hopkinton Morphogen-induzierte Modulation von entzündlichen Antworten
WO1993005751A2 (en) 1991-08-30 1993-04-01 Creative Biomolecules, Inc. Osteogenic proteins in the treatment of bone deseases
AU678345B2 (en) 1991-08-30 1997-05-29 Creative Biomolecules, Inc. Morphogenic protein screening method
DE69233022T2 (de) 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
ES2133333T3 (es) 1991-11-22 1999-09-16 Genentech Inc Tgf-beta para mejorar la recuperacion de las neuronas.
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
CA2141554C (en) 1992-07-31 2003-02-11 David C. Rueger Morphogen-induced nerve regeneration and repair
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
EP0716610B1 (en) 1993-08-26 2006-05-17 Genetics Institute, LLC Human bone morphogenetic proteins for use in neural regeneration
WO1995006656A1 (en) 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
WO1995010611A1 (en) 1993-10-14 1995-04-20 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
AU6787594A (en) 1994-03-10 1995-09-25 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues

Also Published As

Publication number Publication date
KR20000064752A (ko) 2000-11-06
US20030022830A1 (en) 2003-01-30
EP1364655A1 (en) 2003-11-26
JP2000506894A (ja) 2000-06-06
AU734312B2 (en) 2001-06-07
US6407060B1 (en) 2002-06-18
CN1219133A (zh) 1999-06-09
DE69723429T2 (de) 2004-04-22
EP1364655B1 (en) 2010-12-29
EP0894004A1 (en) 1999-02-03
CA2249596A1 (en) 1997-09-25
DE69723429D1 (de) 2003-08-14
WO1997034618A1 (en) 1997-09-25
EP0904093A1 (en) 1999-03-31
ES2201287T3 (es) 2004-03-16
WO1997034626A1 (en) 1997-09-25
US20010039261A1 (en) 2001-11-08
ATE244574T1 (de) 2003-07-15
AU725341B2 (en) 2000-10-12
EP0894004B2 (en) 2007-02-21
ES2201287T5 (es) 2007-10-16
EP0904093A4 (en) 2004-11-17
DE69740089D1 (de) 2011-02-10
EP0894004B1 (en) 2003-07-09
ATE493141T1 (de) 2011-01-15
JP4847634B2 (ja) 2011-12-28
CN1181885C (zh) 2004-12-29
AU2552997A (en) 1997-10-10
CA2249596C (en) 2011-11-08
JP2000507939A (ja) 2000-06-27
US6214796B1 (en) 2001-04-10
AU2582397A (en) 1997-10-10
CA2249368A1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
DE69723429T3 (de) Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
DE69730966T2 (de) Morphogenische behandlung des chronischen nierenversagens
Hamilton et al. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin
DE69928563T2 (de) Abgeben von neurotropischen Wirkstoffen an das Zentralnervensystem
AU2008255016B2 (en) Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
DE69333040T3 (de) Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
DE69535264T2 (de) Verfahren zur behandlung von diabetes mittels kgf
DE60021388T2 (de) Monomeres protein der tgf-beta familie
DE69915310T2 (de) Methoden zur behandlung der salzabhängigen hypertonie
AU693489B2 (en) Method of treating neurological disorders
DE69626034T2 (de) Zusammensetzung für verbesserung der pankreasfunktion
DE69630811T2 (de) Knorpel und knochen bildendes material zur gewebsrückgewinnung
DE19525416A1 (de) Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
DE69826854T2 (de) Therapien zur behandlung von akutem nierenversagen
DE69610826T2 (de) Morphogeninduzierte regenerierung der dentin
EP2352750B1 (en) Buffers for controlling the ph of bone morphogenetic proteins
DE69903612T2 (de) Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten
DE69936638T2 (de) IGF-enthaltende injizierbare Formulierungen, enthaltend Succinat als Puffermittel
DE69738336T2 (de) Verwendung von keratinocyte growth factor-2
DE69832880T2 (de) Frazzled nukleotidsequenzen, expressionsprodukte, zusammensetzungen und verwendungen
DE69727491T2 (de) Verfahren zur verabreichung von wachstumsfaktoren
WO1996008562A1 (de) Biologisch aktive, von neurotrophinen abgeleitete moleküle
DE10317369A1 (de) proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: STRYKER CORP., KALAMAZOO, MICH., US

Owner name: THE GENERAL HOSPITAL CORP., BOSTON, MASS., US